Drug information provided by: Merative, Micromedex®
Ivosidenib is used alone or together with azacitidine to treat newly-diagnosed acute myeloid leukemia (AML) in patients who are 75 years of age or older or who have health problems that prevent the use of certain cancer treatments (chemotherapy). It is also used to treat AML that has come back or has not improved after a previous treatment. Ivosidenib is also used to treat cholangiocarcinoma (bile duct cancer) that has spread or cannot be removed by surgery in patients who have already received a previous treatment. Ivosidenib is also used to treat myelodysplastic syndromes (MDS) that has come back or has not improved after a previous treatment. It is used only in patients who have an isocitrate dehydrogenase-1 (IDH1) mutation in their AML, cholangiocarcinoma, or MDS. Your doctor will test for the presence of this mutation.
This medicine is available only with your doctor's prescription.
This product is available in the following dosage forms:
Portions of this document last updated: Oct. 01, 2024
Copyright: © Merative US L.P. 1973, 2024. All rights reserved. Information is for End User's use only and may not be sold, redistributed or otherwise used for commercial purposes.
妙佑医疗国际不为任何公司或产品背书。广告收入为我们的非营利使命提供支持。
浏览妙佑医疗国际出版社提供的畅销书以及书籍和简报的特别优惠。
您的捐赠可以抵税。请您慷慨解囊,和我们一起进行尖端研究和医护,共同推动医学的改变。